Free Trial

GX Acquisition (GXGX) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

GXGX vs. CHPM, ALUS, SOAC, CYRX, KRRO, ANRO, PGEN, LYEL, NLTX, and ORGO

Should you be buying GX Acquisition stock or one of its competitors? The main competitors of GX Acquisition include CHP Merger (CHPM), Alussa Energy Acquisition (ALUS), Sustainable Opportunities Acquisition (SOAC), Cryoport (CYRX), Korro Bio (KRRO), Alto Neuroscience (ANRO), Precigen (PGEN), Lyell Immunopharma (LYEL), Neoleukin Therapeutics (NLTX), and Organogenesis (ORGO).

GX Acquisition vs.

CHP Merger (NASDAQ:CHPM) and GX Acquisition (NASDAQ:GXGX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, community ranking, dividends, analyst recommendations, institutional ownership and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CHP MergerN/AN/A$22.22MN/AN/A
GX AcquisitionN/AN/A-$49.26MN/AN/A

GX Acquisition received 2 more outperform votes than CHP Merger when rated by MarketBeat users.

CompanyUnderperformOutperform
CHP MergerN/AN/A
GX AcquisitionOutperform Votes
2
100.00%
Underperform Votes
No Votes

71.7% of CHP Merger shares are held by institutional investors. Comparatively, 61.7% of GX Acquisition shares are held by institutional investors. 20.0% of CHP Merger shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

GX Acquisition's return on equity of -245.62% beat CHP Merger's return on equity.

Company Net Margins Return on Equity Return on Assets
CHP MergerN/A -245.62% 8.11%
GX Acquisition N/A -985.20%-6.02%

In the previous week, GX Acquisition's average media sentiment score of 0.00 equaled CHP Merger'saverage media sentiment score.

Company Overall Sentiment
CHP Merger Neutral
GX Acquisition Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CHP Merger
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
GX Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

CHP Merger has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Comparatively, GX Acquisition has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500.

Summary

CHP Merger beats GX Acquisition on 5 of the 7 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GXGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GXGX vs. The Competition

MetricGX AcquisitionPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$112.84M$7.07B$5.29B$8.21B
Dividend YieldN/A2.82%2.72%3.97%
P/E RatioN/A21.65155.1818.65
Price / SalesN/A317.622,087.6691.84
Price / CashN/A32.5835.7134.11
Price / Book22.435.894.944.51
Net Income-$49.26M$147.89M$111.73M$216.36M

GX Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CHPM
CHP Merger
0 of 5 stars
0.00 / 5 stars
$10.18
flat
N/A+0.0%$265.81MN/A0.003
ALUS
Alussa Energy Acquisition
0 of 5 stars
0.00 / 5 stars
$9.50
flat
N/A+0.0%$341.41MN/A-3.141News Coverage
Gap Up
SOAC
Sustainable Opportunities Acquisition
0 of 5 stars
0.00 / 5 stars
$10.62
flat
N/A+0.0%$398.25MN/A0.003News Coverage
CYRX
Cryoport
2.1395 of 5 stars
2.14 / 5 stars
$8.67
+1.9%
$19.43
+124.1%
-43.9%$427.08M$233.26M-3.511,170Short Interest ↑
KRRO
Korro Bio
1.8709 of 5 stars
1.87 / 5 stars
$45.57
-3.0%
$122.50
+168.8%
N/A$422.57M$14.07M0.00101Short Interest ↑
ANRO
Alto Neuroscience
1.0251 of 5 stars
1.03 / 5 stars
$14.96
-2.7%
$35.00
+134.0%
N/A$402.19M$210,000.000.00N/ALockup Expiration
News Coverage
PGEN
Precigen
3.793 of 5 stars
3.79 / 5 stars
N/A$10.00
+∞
+32.8%$401.35M$6.22M0.00202
LYEL
Lyell Immunopharma
2.4246 of 5 stars
2.42 / 5 stars
$1.56
-4.3%
$4.00
+156.4%
-45.7%$397.71M$130,000.00-1.73224Gap Up
NLTX
Neoleukin Therapeutics
0 of 5 stars
0.00 / 5 stars
$42.26
+2.0%
N/A+210.6%$397.16MN/A-13.597
ORGO
Organogenesis
4.7032 of 5 stars
4.70 / 5 stars
$2.90
-1.4%
$4.88
+68.1%
-22.8%$384.46M$435.47M72.52950

Related Companies and Tools

This page (NASDAQ:GXGX) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners